Who wants to live forever? Age cohort differences in attitudes toward life extension

Barnett, Michael D.; Helphrey, Jessica H

doi:10.1016/j.jaging.2021.100931

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of people would like to live to the age of 120 years or more if their health remained good and nearly one half would like an unlimited lifespan [ 1 ]. About one-third of people would be prepared to take life extension or anti-ageing therapies now [ 1 , 2 ]. The possibility that a pill might prevent ageing and increase lifespan is tantalising for most people.…”

Section: Introductionmentioning

confidence: 99%

New horizons in life extension, healthspan extension and exceptional longevity

Couteur

Barzilai

2022

Age and Ageing

View full text Add to dashboard Cite

Many common chronic diseases and syndromes are ageing-related. This raises the prospect that therapeutic agents that target the biological changes of ageing will prevent or delay multiple diseases with a single therapy. Gerotherapeutic drugs are those that target pathways involved in ageing, with the aims of reducing the burden of ageing-related diseases and increasing lifespan and healthspan. The approach to discovering gerotherapeutic drugs is similar to that used to discover drugs for diseases. This includes screening for novel compounds that act on receptors or pathways that influence ageing or repurposing of drugs currently available for other indications. A novel approach involves studying populations with exceptional longevity, in order to identify genes variants linked with longer lifespan and could be targeted by drugs. Metformin, rapamycin and precursors of nicotinamide adenine dinucleotide are amongst the frontrunners of gerotherapeutics that are moving into human clinical trials to evaluate their effects on ageing. There are also increasing numbers of potential gerotherapeutic drugs in the pipeline or being studied in animal models. A key hurdle is designing clinical trials that are both feasible and can provide sufficient clinical evidence to support licencing and marketing of gerotherapeutic drugs.

show abstract

Section: Introductionmentioning

confidence: 99%